Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - SELLAS Life Sciences Group, Inc. | d357046dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 26, 2012
GALENA BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-33958 |
20-8099512 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
310 N. State Street, Suite 208 Lake Oswego, Oregon 97034 |
||||
(Address of Principal Executive Offices) (Zip Code) |
Registrants telephone number, including area code: (855) 855-4253
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
Galena Biopharma, Inc. (we, our, us or the Company) files this Form 8-K/A (Amendment No. 1) to provide updated pro forma financial information related to the disposition of assets reported in our Form 8-K filed on May 2, 2012.
Item 9.01 | Financial Statements and Exhibits. |
(b) | Pro Forma Financial Information. |
Unaudited pro forma condensed consolidated financial information of the Company required by Article 11 of Regulation S-X is attached hereto as Exhibit 99.1 and incorporated by reference herein.
(d) | Exhibits. |
Exhibit No. |
Description | |
99.1 | Unaudited pro forma condensed consolidated financial information. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GALENA BIOPHARMA, INC. | ||||||
Date: May 22, 2012 | By: | /s/ Mark J. Ahn | ||||
Mark J. Ahn President and Chief Executive Officer |